Fibromyalgia is a condition that causes widespread pain all over the body, sleep problems, fatigue, and often emotional and mental distress. People with fibromyalgia may be more sensitive to pain than people without fibromyalgia. The cause of fibromyalgia is not known, but it can be effectively treated and managed. In the U.S. around 4 million people are affected. Women are twice as likely to have fibromyalgia than men.
Swing Therapeutics, a company working on digital therapeutics for people living with chronic conditions, that’s currently focused on fibromyalgia is kicking off its third study. It plans to enroll about 300 participants and will compare one group that receives the company’s ACT digital therapeutic along with standard of care to another group that complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
PROSPER-FM is a multi-center, randomized, non-significant risk device study to evaluate the safety and efficacy of two digital therapy smartphone applications in participants with fibromyalgia. The two primary endpoints are the revised Fibromyalgia Impact Questionnaire (FIQ-R) total score and Patient Global Impression of Change (PGIC).
You can learn more about the study here.
